Boston Scientific to buy Penumbra in $14.5B deal to expand cardiovascular reach

Boston Scientific on Thursday announced plans to acquire Penumbra, a US-based thrombectomy specialist, in a cash-and-stock deal valued at about $14.5 billion, marking one of the largest transactions in the global medical technology sector this year. The acquisition is aimed at strengthening Boston Scientific's cardiovascular and vascular intervention portfolio, as the company looks to capitalise on rising demand for minimally invasive treatments for blood clots, stroke and other life-threatening conditions. ...